Could a diabetes pill save lives in septic shock?
NCT ID NCT07488689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can help people with septic shock—a severe infection that causes organ failure. The drug aims to protect blood vessels and reduce inflammation. About 568 ICU patients will receive either dapagliflozin or a placebo, and researchers will track survival and recovery over 28 days.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Civil, Service de médecine intensive et réanimation, Hôpitaux Universitaires de Strasbourg
Strasbourg, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood markers may foretell brain fog after sepsis
- Can tracking immune chaos in sepsis reveal new treatment targets?
- Blood clot score may predict organ damage in septic shock
- Could a key hormone be missing in septic shock?
- Could a simple mineral cut the need for powerful blood-pressure drugs in septic shock?
- Blood filter could shield vessels in septic shock